Stay updated with breaking news from Cognitive Composite. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared to placebo in patients with preclinical Alzheimer’s disease. 2. Solanezumab did not change the levels of amyloid levels in the brain as compared to placebo in persons with preclinical Alzheimer’s disease. Evidence Rating Level: 1 (Excellent)
A person's ability to self-reflect is associated with cognition and glucose metabolism later in life, a new study finds. Those who engage in more self-reflection had improved cognition, better overall brain health, and increased glucose metabolism later in life.
Subtle preclinical changes may help target treatable disease stages
Apr 16, 2021 THURSDAY, April 15, 2021 (HealthDay News) — There is a longitudinal association of neighborhood-level disadvantage with cortical thinning and cognitive decline, according to a study published online April 14 in Neurology. Jack F. V. Hunt, Ph.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues collected longitudinal magnetic resonance imaging and cognitive testing data from 601 cognitively unimpaired individuals (mean baseline age, 59 years) to examine whether neighborhood-level disadvantage is associated with neurodegeneration a...